Antibodies in blood soon after COVID-19 onset may predict severity

A look at antibodies in patients soon after they were infected with the virus that causes COVID-19 showed key differences between those whose cases remained mild and those who later developed severe symptoms. Learn more >

Prior treatment with cancer drug likely renders COVID-19 vaccine ineffective, study finds

Rituximab, a drug widely used in patients with lymphoma, blunts or eliminates the antibody response to COVID-19 vaccines if it is administered before, Stanford researchers say. Learn more >

Heart Health Month 2022

As we find ourselves adjusting to new health concerns and with advice changing daily, our steadfast hearts continue to keep our bodies active and adaptive so that we don't skip a beat. For American Heart Month this February, Stanford Medicine invites you to send a Valentine to your cardiovascular system by learning more about what makes it tick and how to best protect it.

From innovative new treatments for heart failure, to an in-house service for whole genome sequencing for patients with inherited cardiovascular disease, to diverse genetic research that predicts high cholesterol, to the responsible and equitable use of AI to improve surgeries, to lively cardio events, see how Stanford’s cardiovascular experts are constantly setting the pace for optimal heart health. Explore the stories >

Discovery of hundreds of genes potentially associated with ALS may steer scientists toward treatments

Using machine learning, Stanford Medicine scientists and their colleagues have identified hundreds of genes that could play a role in amyotrophic lateral sclerosis (ALS). Learn more >


We are grateful for the expressions of generosity and desire to help coming from across our community. There are various ways in which you can support our response to this ongoing crisis.

• Improve vaccination awareness
  Stanford researchers are working to understand the diverse views regarding COVID-19 vaccination. We encourage you to help us by completing this one-time COVID-19 Vaccine Views Survey.

• Give blood or plasma
  The Stanford Blood Center urges those who are healthy, and who haven’t been in contact with someone who has COVID-19, to make urgently needed blood donations. Learn more >

• Participate in COVID-19 research
  Stanford Medicine is conducting research that may help to make an important contribution to the fight against COVID-19. If you are eligible for a study, recent research indicates you may contact your study team to provide additional details on how to participate. Learn more >

COVID-19 Community Town Hall

Even the best laid plans of mice and men... From the Office of Community Engagement, and the Department of Epidemiology and Population Health, a new Town Hall meeting addresses long COVID—research, treatment, and recovery—and the existing new versions of the Omicron variant. Watch the video >

Taking Care of Yourself and Others

Staying active is important — especially for older adults

Randall Stafford, MD, PhD, discusses the importance—and benefits—of physical activity, particularly for aging adults. Learn more >

Research explores how scammers take advantage of COVID-19

Scammers have exploited the loosened regulations, and people have been warned not to scan unknown emails or websites with links to suspicious websites with unfamiliar domain names. Learn more >

Deerfield, Stanford University create Porter Alliance for Innovative Medicines

Deerfield Management, a health-care investment firm, has committed up to $130 million to support innovative translational research at Stanford. Learn more >

A blood test to predict surgical complications?

Stanford researchers have published a preliminary study showing that a blood-based test could predict surgical complications, such as infection, and may therefore help the most from getting up and walking again in a surgery. Learn more >

If you would prefer not to receive any fundraising communications from Medical Center Development, please visit medicalgiving.stanford.edu/opt-out.html or leave a detailed message at 844.427.3491 to indicate that preference.

To subscribe to this newsletter via email, please check here.